(Press-News.org) ANN ARBOR, Mich. - It started out as a treatment for arthritis. But steered by science, it could become a first new approach in two decades for treating the damage that diabetes inflicts on the kidneys of millions of people.
This past weekend, University of Michigan Medical School researchers and their colleagues presented promising results from a clinical trial of the experimental drug baricitinib in people with diabetic kidney disease. In a randomized, controlled Phase II study, it reduced a key sign of kidney damage, with higher doses producing the largest effect, few side effects, and signs of sustained impact even after patients stopped taking it.
U-M researchers not only helped conduct the clinical study - their scientific discoveries set the trial in motion. It's a fast-track example of the new treatment-development approach known as precision medicine.
The trial results presented this week at the American Diabetes Association Scientific Sessions come just three and a half years after the U-M research team linked up with the company that makes the drug, Eli Lilly & Co.
That connection resulted from the work of a team led by Matthias Kretzler, M.D. and Frank Brosius, M.D., which had worked for years to pinpoint the importance of a cell-signaling system called JAK-STAT in diabetic kidney disease.
By plowing through massive amounts of data on abnormal genetic activity in diseased human kidney tissue, and studying specially bred mice, the team showed JAK-STAT was over-active in multiple kidney cells damaged by diabetes.
But JAK-STAT also plays a key role in diseases where immune-system cells attack normal tissues - such as rheumatoid arthritis. Lilly scientists had developed baricitinib to calm the painful, inflamed joints of RA patients, and had received FDA permission to do trials that showed the drug's safety and impact.
When they learned that Kretzler was scheduled to speak about his research to another group at Lilly, they went to his talk and raised the possibility of using baricitinib against diabetic kidney disease. The international clinical trial, which enrolled 129 adult patients, began quickly -- just 14 months after that meeting.
"This is the first example of implementing precision medicine in diabetic kidney disease, which affects 8 million Americans and will surely affect more as the growing diabetes epidemic continues," says Kretzler. "It shows that the full translational research pipeline is in place, where we can study disease mechanisms, test our findings in model systems, identify drug candidates, find the right partners to take it to a clinical trial, and complete the trial - in 42 months."
The trial showed baricitinib reduced a measure of kidney dysfunction called urinary albumin/ creatinine ratio or UACR, substantially compared with placebo after six months. It also showed that patients had lower levels of two compounds in urine or blood that indicate inflammation in the kidneys, called IP-10 and sTNFR2. The only significant side effect was mild anemia in the group that received the highest dose, which was expected based on previous research.
Brosius directed the animal research studies and co-led the multi-institutional clinical trial. He notes that treatment of diabetic kidney disease costs the U.S. billions of dollars yearly. Currently, the standard approach to treating kidney damage in people with diabetes is to control blood pressure using decades-old drugs called ACE inhibitors and ARBs.
"The long-term effects of America's obesity and diabetes epidemics means that millions more kidneys are at risk. So America urgently needs new approaches to stem the damage that diabetes inflicts on kidney cells," says Brosius, who heads U-M's Division of Nephrology and the Michigan Kidney Translational Core Center that helped support this work. "So does the world, as nations like China feel the effects of obesity and diabetes epidemics."
Promise of university-industry cooperation
The new trial results are the first step in determining if baricitinib or other drugs that act on the JAK-STAT system could fight these effects. But they also show promise of combining basic university research, which can uncover specific targets for precise-acting drugs, with drug compounds developed by pharmaceutical companies.
Even drugs left on the shelf years ago, or already in use for other diseases, could be tested for new uses based on research findings from teams like the U-M group.
The U-M Medical School's Business Development team helped make the linkage between U-M and Lilly possible, and has brokered other agreements under which companies sponsor research by U-M teams to find specific targets for drugs.
The basic research was funded by the National Institutes of Health, the European Union and the Juvenile Diabetes Research Foundation International. This includes the development of a bank of diseased kidney tissue taken during patient biopsies, the creation of a "humanized" mouse model, and high-level computing resources.
Other faculty members at U-M are looking for pathways involved in other ways that diabetes damages organs and tissues - from nerves to eyes. The approach, called systems biology, combines detailed studies of biological processes with advanced computing to create a computer model of a disease.
"Not only does system biology works for finding new drug targets and repurposing drug compounds that already have been tested safely in humans. It can work quickly," says Kretzler.
INFORMATION:
Read the abstract of results presented at the ADA meeting:
http://www.abstractsonline.com/pp8/#!/3699/presentation/12757
Many cancer patients survive treatment only to have a recurrence within a few years. Recurrences and tumor spreading are likely due to cancer stem cells that can be tough to kill with conventional cancer drugs. But now researchers have designed nanoparticles that specifically target these hardy cells to deliver a drug. The nanoparticle treatment, reported in the journal ACS Nano, worked far better than the drug alone in mice.
Anti-cancer drugs can often shrink tumors but don't kill cancer stem cells (CSCs). Although CSCs might only make up a small part of a tumor, their ...
As many of the world's nations prepare and implement plans to cut greenhouse gas emissions, researchers say another critical factor needs to be considered. A new study has found for the first time that efforts to keep global temperatures in check will likely lead to more people going hungry. That risk, they say in the ACS journal Environmental Science & Technology, doesn't negate the need for mitigation but highlights the importance of comprehensive policies.
Previous studies have shown that climate change reduces how much food farms can produce, which could lead to ...
When Typhoon Haiyan slammed into the Philippines in 2013, thousands of people were killed, in part because they didn't know it was coming or didn't know how to protect themselves.
Could an increased use of social media, particularly on the part of the nation's government, have made a difference?
While that question remains open, it is clear that social media should play a larger role in emergency preparedness, says Bruno Takahashi, a Michigan State University assistant professor of journalism who studies the issue.
Using the Philippines' typhoon as a case study, Takahashi ...
Although the Universe may seem spacious most galaxies are clumped together in groups or clusters and a neighbour is never far away. But this galaxy, known as NGC 6503, has found itself in a lonely position, shown here at the edge of a strangely empty patch of space called the Local Void. This new NASA/ESA Hubble Space Telescope image shows a very rich set of colours, adding to the detail seen in previous images.
NGC 6503 is only some 18 million light-years away from us in the constellation of Draco (The Dragon), making it one of the closest neighbours from our Local Group. ...
The stuffy noses and sinus pressure of head colds are uncomfortable, but for most people, they go away within days. For those with chronic sinusitis, however, those symptoms and others drag on for weeks. Now scientists are onto a potential new therapy that could address one of the underlying factors associated with the condition. They describe their work in the ACS journal Molecular Pharmaceutics.
In the body, nitric oxide (NO) plays a critical role in immunity. Researchers have found that this simple molecule is an important antimicrobial agent that helps prevent sinus ...
To some scientists studying climate change, boreal peatlands are considered a potential ticking time bomb. With huge stores of carbon in peat, the fear is that rising global temperatures could cause the release of massive amounts of CO2 from the peatlands into the atmosphere--essentially creating a greenhouse gas feedback loop.
A new study by researchers at the University of South Carolina and University of California Los Angeles challenges that notion, and demonstrates that the effect of temperature increases on peat storage could be minor.
Funded by the National ...
This news release is available in German.
Human teeth have to serve for a lifetime, despite being subjected to huge forces. But the high failure resistance of dentin in teeth is not fully understood. An interdisciplinary team led by scientists of Charite Universitaetsmedizin Berlin has now analyzed the complex structure of dentin. At the synchrotron sources BESSY II at HZB, Berlin, Germany, and the European Synchrotron Radiation Facility ESRF, Grenoble, France, they could reveal that the mineral particles are precompressed.
The internal stress works against crack ...
Chicago, June 10, 2015 - Patients diagnosed with an advanced form of metastatic non-small cell lung cancer (NSCLC) may benefit from surgical resection (removal of all or part of the lung) in combination with chemotherapy and radiation therapy, according to an article in the June 2015 issue of The Annals of Thoracic Surgery.
Key points
Patients diagnosed with stage IIIB NSCLC may benefit from multimodality treatment that combines surgical resection in combination with chemotherapy or radiation therapy.
Surgery should be added to the treatment regimen only for carefully ...
Dangerous heart rhythms called arrhythmias, often caused by undiagnosed heart conditions, can cause sudden cardiac arrests that take the lives of seemingly healthy young men and women including sports people.
A healthy, functioning heart has a regular electrical impulse that causes the heart to beat and pump blood around the body. If this impulse is interrupted or becomes irregular, it causes an abnormal heartbeat, called an arrhythmia. Arrhythmias can be a long-term condition, treated with medication or surgery or they can occur unexpectedly, suddenly stopping the heart ...
Europe's most homophobic countries may be paving the way for a rise in HIV cases among gay and bisexual men, according to new research published in the journal AIDS.
An international team of researchers from Europe and the US looked at HIV-related service use, need and behaviours among 175,000 gay or bisexual men living in 38 European countries with differing levels of national homophobia.
They found that men in homophobic countries had fewer sexual partners and were less likely to be diagnosed with HIV. However, they also found those men knew less about HIV, were less ...
